Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Medtronic
Colorcon
Merck
Fish and Richardson
Baxter
Daiichi Sankyo
Julphar
Deloitte
Teva

Generated: August 17, 2017

DrugPatentWatch Database Preview

Sarepta Theraps Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SAREPTA THERAPS INC, and when can generic versions of SAREPTA THERAPS INC drugs launch?

SAREPTA THERAPS INC has one approved drug.

There are four US patents protecting SAREPTA THERAPS INC drugs.

There are one hundred and five patent family members on SAREPTA THERAPS INC drugs in nineteen countries.

Summary for Applicant: Sarepta Theraps Inc

Patents:4
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-002Sep 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-001Sep 19, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-001Sep 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-001Sep 19, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Sarepta Theraps Inc
EXONDYS 51
eteplirsen
SOLUTION;IV (INFUSION)206488-002Sep 19, 2016RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Sarepta Theraps Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,314,072Antisense antibacterial method and compound► Subscribe
8,455,635Antisense oligonucleotides for inducing exon skipping and methods of use thereof► Subscribe
8,084,433Antisense antiviral compound and method for treating ssRNA viral infection► Subscribe
8,785,410Antisense composition and method for treating muscle atrophy► Subscribe
9,441,229Antisense oligonucleotides for inducing exon skipping and methods of use thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sarepta Theraps Inc Drugs

Country Document Number Estimated Expiration
European Patent Office1682073► Subscribe
Japan2016516066► Subscribe
European Patent Office2735568► Subscribe
European Patent Office1814898► Subscribe
European Patent Office1814596► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
AstraZeneca
Healthtrust
Covington
Chinese Patent Office
Express Scripts
Daiichi Sankyo
Boehringer Ingelheim
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot